NO2017025I1 - Rekombinant FSH (rFSH) innbefattende alfa2,3-sialylering og alfa2,6-sialylering hvor 80% eller mer av den totale sialylering er alfa2,3-sialylering og hvor fra 5% til 20% av den totale sialylering er alfa2,6- sialylering, spesielt follitropin delta. - Google Patents

Rekombinant FSH (rFSH) innbefattende alfa2,3-sialylering og alfa2,6-sialylering hvor 80% eller mer av den totale sialylering er alfa2,3-sialylering og hvor fra 5% til 20% av den totale sialylering er alfa2,6- sialylering, spesielt follitropin delta.

Info

Publication number
NO2017025I1
NO2017025I1 NO2017025C NO2017025C NO2017025I1 NO 2017025 I1 NO2017025 I1 NO 2017025I1 NO 2017025 C NO2017025 C NO 2017025C NO 2017025 C NO2017025 C NO 2017025C NO 2017025 I1 NO2017025 I1 NO 2017025I1
Authority
NO
Norway
Prior art keywords
sialylation
alpha2
total
rfsh
follitropin
Prior art date
Application number
NO2017025C
Other languages
English (en)
Norwegian (no)
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39717519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2017025(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of NO2017025I1 publication Critical patent/NO2017025I1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99006—N-Acetyllactosaminide alpha-2,3-sialyltransferase (2.4.99.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO2017025C 2008-04-16 2017-06-06 Rekombinant FSH (rFSH) innbefattende alfa2,3-sialylering og alfa2,6-sialylering hvor 80% eller mer av den totale sialylering er alfa2,3-sialylering og hvor fra 5% til 20% av den totale sialylering er alfa2,6- sialylering, spesielt follitropin delta. NO2017025I1 (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4542408P 2008-04-16 2008-04-16
EP08251528 2008-04-25
EP09733497.3A EP2268666B1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
EP13193214.7A EP2722339A1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation
EP14178729.1A EP2808340B1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation

Publications (1)

Publication Number Publication Date
NO2017025I1 true NO2017025I1 (no) 2017-06-06

Family

ID=39717519

Family Applications (4)

Application Number Title Priority Date Filing Date
NO2017025C NO2017025I1 (no) 2008-04-16 2017-06-06 Rekombinant FSH (rFSH) innbefattende alfa2,3-sialylering og alfa2,6-sialylering hvor 80% eller mer av den totale sialylering er alfa2,3-sialylering og hvor fra 5% til 20% av den totale sialylering er alfa2,6- sialylering, spesielt follitropin delta.
NO2017050C NO2017050I1 (no) 2008-04-25 2017-09-28 Rekombinant FSH (folikkel-stimulerende hormon)
NO2025006C NO2025006I1 (no) 2008-04-25 2025-01-16 Follitropin delta
NO2025032C NO2025032I1 (no) 2008-04-25 2025-07-14 Follitropin delta

Family Applications After (3)

Application Number Title Priority Date Filing Date
NO2017050C NO2017050I1 (no) 2008-04-25 2017-09-28 Rekombinant FSH (folikkel-stimulerende hormon)
NO2025006C NO2025006I1 (no) 2008-04-25 2025-01-16 Follitropin delta
NO2025032C NO2025032I1 (no) 2008-04-25 2025-07-14 Follitropin delta

Country Status (29)

Country Link
US (6) US8951967B2 (https=)
EP (7) EP2722339A1 (https=)
JP (7) JP2011519359A (https=)
KR (5) KR20170110741A (https=)
CN (3) CN105906703A (https=)
AR (1) AR071479A1 (https=)
AU (5) AU2009237479B2 (https=)
BR (1) BRPI0910461B8 (https=)
CA (1) CA2725257A1 (https=)
CY (1) CY1115413T1 (https=)
DK (6) DK2268666T3 (https=)
ES (5) ES2629392T3 (https=)
FI (4) FI4015527T3 (https=)
FR (3) FR17C1020I2 (https=)
HR (5) HRP20140535T1 (https=)
HU (9) HUE068565T2 (https=)
IL (2) IL208538A (https=)
LT (8) LT3045471T (https=)
MX (3) MX348622B (https=)
NO (4) NO2017025I1 (https=)
NZ (1) NZ588381A (https=)
PL (6) PL3144318T3 (https=)
PT (6) PT3144318T (https=)
RU (3) RU2537268C2 (https=)
SA (1) SA109300228B1 (https=)
SI (6) SI2268666T1 (https=)
TW (1) TWI488640B (https=)
WO (1) WO2009127826A1 (https=)
ZA (1) ZA201007373B (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
TWI532495B (zh) * 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
EP2621517B2 (en) 2010-09-29 2023-10-11 Ferring B.V. Composition for use in treating infertility
WO2012050175A1 (ja) 2010-10-15 2012-04-19 日本ケミカルリサーチ株式会社 糖鎖の非還元末端がマンノース残基である糖蛋白質の製造方法
US9757469B2 (en) 2011-03-31 2017-09-12 Ferring B.V. Pharmaceutical preparation
EP2717904A1 (en) 2011-06-06 2014-04-16 Ferring BV Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
WO2013093760A2 (en) * 2011-12-19 2013-06-27 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
WO2013161958A1 (ja) * 2012-04-27 2013-10-31 日本ケミカルリサーチ株式会社 新規な発現ベクター
EP2824176A1 (en) * 2013-07-11 2015-01-14 Siamed'xpress Methods for producing sialylated therapeutic proteins
JP6652334B2 (ja) 2014-05-31 2020-02-19 Ｊｃｒファーマ株式会社 ウリジンとｎ−アセチル−ｄ−マンノサミンとを含有する培地
EP3237608B1 (en) * 2014-12-22 2019-10-09 F. Hoffmann-La Roche AG Cmp-dependent sialidase activity
EP3662925B1 (en) 2015-04-17 2021-04-07 Ferring B.V. Composition comprising fsh for treatment of infertility
WO2016207353A1 (en) * 2015-06-26 2016-12-29 Ferring B.V. Methods of purification and/or viral inactivation
EP3205719A1 (en) * 2016-02-15 2017-08-16 CEVEC Pharmaceuticals GmbH Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
EP3382014A1 (en) * 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
EP3441471A1 (en) 2017-08-08 2019-02-13 CEVEC Pharmaceuticals GmbH Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines
US11744879B2 (en) 2017-09-01 2023-09-05 Ferring B.V. Recombinant FSH composition for controlled ovarian stimulation
RS66871B1 (sr) 2018-04-30 2025-06-30 Ferring Bv Kompozicija za kontrolisanu stimulaciju jajnika
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
WO2021081670A1 (en) * 2019-11-01 2021-05-06 The University Of British Columbia Compositions and methods for sialylated mucin-type o-glycosylation of therapeutic proteins
TW202237173A (zh) 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法
AU2022451605A1 (en) 2022-04-01 2024-09-26 Ferring B.V. Mixed protocol for treatment of infertility
WO2023227761A1 (en) 2022-05-26 2023-11-30 Ferring B.V. Compositions and methods for treatment of infertility in males
AU2023302100A1 (en) 2022-07-08 2025-01-02 Ferring B.V. Compositions and methods for intrauterine insemination (iui)
AR133300A1 (es) 2023-07-20 2025-09-17 Ferring Bv Micropartículas cargadas con fármaco de liberación prolongada

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US5541083A (en) 1989-10-24 1996-07-30 The Regents Of The University Of California Method for producing secretable glycosyltransferases and other golgi processing enzymes
SI0833934T2 (sl) 1995-06-15 2013-04-30 Crucell Holland B.V. Pakirni sistemi za humani rekombinantni adenovirus za uporabo v genski terapiji
JP3559652B2 (ja) * 1996-06-25 2004-09-02 グローリー工業株式会社 売上精算システムの管理装置
IL122732A0 (en) * 1997-01-15 1998-08-16 Akzo Nobel Nv Liquid gonadotropin-containing formulation its preparation and a device containing same
CA2278178C (en) 1997-01-16 2012-09-25 Cytel Corporation Practical in vitro sialylation of recombinant glycoproteins
JPH1111665A (ja) 1997-06-28 1999-01-19 Shibuya Kogyo Co Ltd 無菌エア搬送コンベヤ装置
TWI235158B (en) * 1997-09-01 2005-07-01 Kirin Brewery Human thrombopoietin produced by human established cell lines, processes foe preparing the same, and pharmaceutical composition comprising the same
PT1176976E (pt) 1999-05-07 2006-11-30 Applied Research Systems Utilização de lh administrada na fase folicular média e tardia para o tratamento de mulheres anovulatórias.
JP2002011665A (ja) 2000-06-28 2002-01-15 Sintokogio Ltd ショットブラスト装置モニタシステム
IL140110A0 (en) 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
ES2261740T3 (es) * 2001-10-22 2006-11-16 Applied Research Systems Ars Holding N.V. Composiciones de fsh con alto grado de sialilacion y su uso para la preparacion de medicamentos.
CA2756610C (en) 2001-10-29 2015-08-25 Crucell Holland B.V. Methods for producing proteins having n-linked glycans comprising (sialyl-) lewis x or lacdinac structures
KR100979025B1 (ko) 2001-12-07 2010-08-30 크루셀 홀란드 비.브이. 바이러스, 바이러스 단리물 및 백신의 생산
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
US20080015142A1 (en) * 2003-12-03 2008-01-17 Defrees Shawn Glycopegylated Follicle Stimulating Hormone
DE602005022675D1 (de) 2004-02-04 2010-09-16 Centre Nat Rech Scient Verfahren zur identifizierung von glykoformspezifischen antikörpern
EP1725673A1 (en) 2004-02-13 2006-11-29 Glycotope Gmbh Sialytated glycoproteins-process conditions and an efficient method for their production
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
US8790322B2 (en) 2010-08-03 2014-07-29 King Saud University Stoma coat
WO2012016576A1 (en) 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
EP2621517B2 (en) 2010-09-29 2023-10-11 Ferring B.V. Composition for use in treating infertility
US9757469B2 (en) 2011-03-31 2017-09-12 Ferring B.V. Pharmaceutical preparation
EP2717904A1 (en) 2011-06-06 2014-04-16 Ferring BV Pharmaceutical preparation comprising recombinant fsh
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
AR100132A1 (es) 2014-04-18 2016-09-14 Glycotope Gmbh Un método para hiperestimulación ovárica controlada para estimular el desarrollo de múltiples folículos ováricos en un sujeto femenino

Also Published As

Publication number Publication date
BRPI0910461A2 (pt) 2018-03-27
HUS1700025I1 (hu) 2017-06-28
JP2018021037A (ja) 2018-02-08
ES2989729T3 (es) 2024-11-27
EP4015527B1 (en) 2025-01-22
DK3144318T3 (da) 2020-12-07
AR071479A1 (es) 2010-06-23
EP3045471A1 (en) 2016-07-20
NZ588381A (en) 2012-05-25
RU2682270C2 (ru) 2019-03-18
RU2010141908A (ru) 2012-05-27
WO2009127826A1 (en) 2009-10-22
HUE068565T2 (hu) 2025-01-28
SA109300228B1 (ar) 2014-04-08
NO2025032I1 (no) 2025-07-14
EP2268666B1 (en) 2014-03-12
LTPA2017018I1 (lt) 2017-06-26
PL3098234T3 (pl) 2025-01-07
PT3045471T (pt) 2017-06-14
CY1115413T1 (el) 2017-01-04
FR17C1020I1 (https=) 2020-04-10
HUE033830T2 (en) 2018-01-29
CN102066414A (zh) 2011-05-18
HUE030652T4 (en) 2017-09-28
EP3144318B1 (en) 2020-09-23
HUS2500029I1 (hu) 2025-07-28
JP6762916B2 (ja) 2020-09-30
DK3045471T3 (en) 2017-06-26
ES2629392T3 (es) 2017-08-09
JP6486310B2 (ja) 2019-03-20
FIC20250003I1 (fi) 2025-01-15
BRPI0910461B8 (pt) 2021-05-25
AU2014203277A1 (en) 2014-07-24
NO2025006I1 (no) 2025-01-16
MX2010011343A (es) 2011-01-20
PL4015527T3 (pl) 2025-05-26
ES2468318T3 (es) 2014-06-16
JP2015120696A (ja) 2015-07-02
MX355457B (es) 2018-04-19
US20160347811A1 (en) 2016-12-01
KR20160056960A (ko) 2016-05-20
BRPI0910461A8 (pt) 2018-10-16
US9771407B2 (en) 2017-09-26
AU2017204258A1 (en) 2017-07-20
JP2022031652A (ja) 2022-02-22
ZA201007373B (en) 2011-06-29
DK2268666T3 (da) 2014-05-12
EP3098234B1 (en) 2024-07-31
LT4015527T (lt) 2025-04-10
IL208538A0 (en) 2010-12-30
IL230571A (en) 2015-11-30
SI3144318T1 (sl) 2020-12-31
JP7316905B2 (ja) 2023-07-28
US11952407B2 (en) 2024-04-09
EP2722339A1 (en) 2014-04-23
RU2745557C3 (ru) 2021-12-10
ES2610277T3 (es) 2017-04-26
HRP20140535T1 (hr) 2014-07-18
HRP20170958T1 (hr) 2017-09-22
HUS1700036I1 (hu) 2017-10-30
AU2009237479A1 (en) 2009-10-22
RU2014141994A3 (https=) 2018-05-28
SI4015527T1 (sl) 2025-05-30
JP2017060476A (ja) 2017-03-30
FIC20250025I1 (fi) 2025-07-11
US12516094B2 (en) 2026-01-06
EP2268666A1 (en) 2011-01-05
US20110105398A1 (en) 2011-05-05
LT2808340T (lt) 2016-11-10
FR25C1025I1 (fr) 2025-09-19
HUE030652T2 (en) 2017-05-29
AU2014203277B2 (en) 2017-04-06
LT3045471T (lt) 2017-07-10
HRP20161520T1 (hr) 2016-12-30
US20240327487A1 (en) 2024-10-03
RU2745557C1 (ru) 2021-03-29
PT3144318T (pt) 2020-11-04
EP3144318A1 (en) 2017-03-22
AU2017225020B2 (en) 2019-11-14
HUE071059T2 (hu) 2025-07-28
US20210332099A1 (en) 2021-10-28
PL2268666T3 (pl) 2014-08-29
US20180079794A1 (en) 2018-03-22
FR25C1003I1 (fr) 2025-02-28
RU2014141994A (ru) 2016-05-10
JP2024038000A (ja) 2024-03-19
EP2808340A1 (en) 2014-12-03
KR20110005863A (ko) 2011-01-19
SI3098234T1 (sl) 2024-10-30
PT2268666E (pt) 2014-06-25
LT3098234T (lt) 2024-09-10
EP3098234A1 (en) 2016-11-30
PL3144318T3 (pl) 2021-02-08
CN105906703A (zh) 2016-08-31
KR20170110741A (ko) 2017-10-11
EP2808340B1 (en) 2016-08-17
CN105906702A (zh) 2016-08-31
JP2020040956A (ja) 2020-03-19
DK2808340T3 (en) 2016-12-05
EP3045471B1 (en) 2017-03-29
AU2017204259A1 (en) 2017-07-20
US9546204B2 (en) 2017-01-17
HUS1700024I1 (hu) 2017-06-28
SI3045471T1 (sl) 2017-07-31
MX348622B (es) 2017-06-22
SI2268666T1 (sl) 2014-07-31
HK1146284A1 (en) 2011-05-20
KR20180095140A (ko) 2018-08-24
AU2017225020A1 (en) 2017-09-28
LTPA2017029I1 (lt) 2017-10-10
DK3098234T3 (da) 2024-10-21
US20150065695A1 (en) 2015-03-05
PL3045471T3 (pl) 2017-10-31
SI2808340T1 (sl) 2016-12-30
BRPI0910461B1 (pt) 2021-02-23
RU2537268C2 (ru) 2014-12-27
EP4015527A1 (en) 2022-06-22
FI3098234T3 (fi) 2024-10-31
LTPA2025505I1 (https=) 2025-02-10
KR101622944B1 (ko) 2016-05-23
FI4015527T3 (fi) 2025-04-29
US10995128B2 (en) 2021-05-04
TWI488640B (zh) 2015-06-21
HRP20250313T1 (hr) 2025-05-09
PT2808340T (pt) 2016-11-21
IL208538A (en) 2014-03-31
KR102108377B1 (ko) 2020-05-08
US8951967B2 (en) 2015-02-10
LTPA2025525I1 (https=) 2025-07-25
PL2808340T3 (pl) 2017-02-28
AU2014203277C1 (en) 2017-07-27
HK1199039A1 (en) 2015-06-19
AU2017204258B2 (en) 2017-08-17
ES3023526T3 (en) 2025-06-02
HUS2500008I1 (hu) 2025-02-28
CA2725257A1 (en) 2009-10-22
FR17C1020I2 (fr) 2020-04-10
TW200948378A (en) 2009-12-01
PT3098234T (pt) 2024-10-21
AU2017204259B2 (en) 2017-08-17
KR20190092608A (ko) 2019-08-07
HRP20241187T1 (hr) 2024-12-06
NO2017050I1 (no) 2017-09-28
JP2011519359A (ja) 2011-07-07
PT4015527T (pt) 2025-04-10
DK4015527T3 (da) 2025-04-14
AU2009237479B2 (en) 2014-05-15

Similar Documents

Publication Publication Date Title
NO2017025I1 (no) Rekombinant FSH (rFSH) innbefattende alfa2,3-sialylering og alfa2,6-sialylering hvor 80% eller mer av den totale sialylering er alfa2,3-sialylering og hvor fra 5% til 20% av den totale sialylering er alfa2,6- sialylering, spesielt follitropin delta.
WO2007106690A3 (en) Degenerate nucleobase analogs
CN106573011A8 (zh) 取代的核苷、核苷酸和其类似物
EP4349405A3 (en) Respiratory virus vaccines
HK1216535A1 (zh) 取代的核苷、核苷酸及其類似物
WO2018031818A3 (en) Substituted nucleosides, nucleotides and analogs thereof
SG10201804835VA (en) Substituted nucleosides, nucleotides and analogs thereof
HK1245800A1 (zh) 被取代的核苷、核苷酸及其类似物
WO2010101663A3 (en) Live attenuated influenza virus vaccines comprising microrna response elements
JP2011527560A5 (https=)
WO2007098267A3 (en) Pseudoinfectious flavivirus and uses thereof
HK1224229A1 (zh) 取代的核苷，核苷酸及其类似物
JP2012530597A5 (https=)
WO2011139699A3 (en) 5' modified nucleosides and oligomeric compounds prepared therefrom
WO2015025221A3 (en) System and method for capturing and using move data
WO2007109600A3 (en) Extractions and methods comprising elder species
MX2010001849A (es) Depsipeptidos ciclicos.
HK1217295A1 (zh) 4'-疊氮基，3'-脫氧基-3'-氟取代的核苷衍生物
MX2020011677A (es) Proceso para preparar esteres de acido lactico y acido 2-hidroxi-3-butenoico o analogos de alfa-hidroxi-metionina a partir de azucares.
PT4077293T (pt) Tratamento térmico de ácido 2,5-furandicarboxílico e composição de ácido carboxílico resultante
WO2008133759A3 (en) Antiviral peptides
PL2247369T3 (pl) Struktura katalizatora dwutlenku tytanu do procesów do 1000°c i jego produkcja
NO20090958L (no) Behandling av revmatismesykdom med langsom frigivelse av glukokortikoid
DK2247573T3 (da) Kulsyre- og svovlsyresalte af 3-(2,2,2-trimethylhydrazinium)propionatstere af anvendelse deraf til fremstilling og 3-(2,2,2-trimethylhydrazinium)propionat-dihydrat
UA96627C2 (ru) Сухой экстракт из pelargonium sidoides ta pelargonium reniforme, способ его получения и продукты на его основе